uniQure N.V. (QURE) Stock Price

QUREStock

$21.78−63.69%52W

Market Cap$1.51B

P/E—

PEG Ratio—

Div yield—

Beta1.07

QURE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)17.54%

Price vs S&P 500 (4W)-49.52%

VGM Score40.88

Book Value / Share (Quarterly)$4.67

P/TBV (Annual)11.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.73%

Cash Flow / Share (Quarterly)$-2.33

Price vs S&P 500 (YTD)-20.91%

Gross Margin (TTM)92.49%

Net Profit Margin (TTM)-1350.73%

EPS (TTM)$-4.05

10-Day Avg Trading Volume2.17M

EPS Excl Extra (TTM)$-4.05

Revenue Growth (5Y)-15.56%

EPS (Annual)$-3.46

ROI (Annual)-27.57%

Gross Margin (Annual)89.53%

Net Profit Margin (5Y Avg)-824.52%

Cash / Share (Quarterly)$11.69

Revenue Growth QoQ (YoY)11.00%

ROA (Last FY)-24.12%

Revenue Growth TTM (YoY)30.24%

EBITD / Share (TTM)$-2.97

ROE (5Y Avg)-54.23%

Operating Margin (TTM)-1071.53%

Cash Flow / Share (Annual)$-2.86

P/B Ratio4.66x

P/B Ratio (Quarterly)9.66x

Net Income / Employee (Annual)$-900,300

EV / Revenue (TTM)87.69x

Net Interest Coverage (TTM)-9.23x

ROA (TTM)-29.01%

EV / EBITDA (TTM)5.31x

EPS Incl Extra (Annual)$-3.46

Current Ratio (Annual)10.43x

Quick Ratio (Quarterly)9.89x

3-Month Avg Trading Volume2.21M

52-Week Price Return-63.69%

Revenue / Employee (TTM)$84,500

Tangible BV / Share (Quarterly)$3.78

P/S Ratio (Annual)93.85x

Asset Turnover (Annual)0.02x

52-Week High$71.50

Operating Margin (5Y Avg)-738.32%

EPS Excl Extra (Annual)$-3.46

CapEx CAGR (5Y)-45.93%

Tangible BV CAGR (5Y)-16.87%

26-Week Price Return27.44%

Quick Ratio (Annual)10.10x

13-Week Price Return-45.89%

Total Debt / Equity (Annual)2.63x

Current Ratio (Quarterly)10.01x

Enterprise Value$1.64B

Revenue / Share Growth (5Y)-19.78%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-15.47%

Revenue / Employee (Annual)$72,800

Inventory Turnover (Annual)3.05x

Pretax Margin (Annual)-1201.02%

Cash / Share (Annual)$9.99

3-Month Return Std Dev88.66%

Gross Margin (5Y Avg)65.59%

Net Income / Employee (TTM)$-1,141,200

ROE (Last FY)-100.04%

Net Interest Coverage (Annual)-4.60x

EPS Basic Excl Extra (Annual)$-3.46

P/FCF (TTM)40.62x

Receivables Turnover (TTM)3.28x

Total Debt / Equity (Quarterly)1.66x

EPS Incl Extra (TTM)$-4.05

Receivables Turnover (Annual)2.74x

ROI (TTM)-33.48%

P/S Ratio (TTM)80.91x

Pretax Margin (5Y Avg)-813.47%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$2.02

Price vs S&P 500 (52W)-79.23%

Year-to-Date Return-8.98%

5-Day Price Return-0.27%

EPS Normalized (Annual)$-3.46

ROA (5Y Avg)-16.30%

Net Profit Margin (Annual)-1236.00%

Month-to-Date Return-9.85%

Cash Flow / Share (TTM)$-4.60

EBITD / Share (Annual)$-2.97

Operating Margin (Annual)-1151.38%

LT Debt / Equity (Annual)2.63x

ROI (5Y Avg)-18.15%

LT Debt / Equity (Quarterly)1.66x

EPS Basic Excl Extra (TTM)$-4.05

P/TBV (Quarterly)11.95x

P/B Ratio (Annual)7.41x

Inventory Turnover (TTM)3.05x

Pretax Margin (TTM)-1313.04%

Book Value / Share (Annual)$3.19

Price vs S&P 500 (13W)-48.57%

Beta1.07x

P/FCF (Annual)5.58x

Revenue / Share (TTM)$0.28

ROE (TTM)-111.96%

52-Week Low$8.73

vGradeD

gGradeC

mGradeC

vgmGradeC

QURE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 29, 2026	-$0.71	-$1.07	-51.25%(-$0.36)
Q1 2026	May 5, 2026	-$0.75	-$0.73	+3.34%(+$0.03)
Q4 2025	Mar 2, 2026	-$0.78	-$0.47	+39.25%(+$0.31)
Q3 2025	Nov 10, 2025	-$0.75	-$1.19	-59.78%(-$0.45)
Q2 2025	Jul 29, 2025	-$0.76	-$0.60	+21.14%(+$0.16)

QURE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.05

4.14

4.25

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
QUREuniQure N.V.	D	C	C	80.9x	30.2%	92.5%	—	$21.78
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About uniQure N.V.

uniQure NV is a gene therapy company developing treatments for hemophilia, Huntington's disease, and cardiovascular diseases. The company has established a collaboration with Bristol Myers Squibb to advance its cardiovascular gene therapy pipeline.